Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
  E-Commerce
  Information technology
  Internet
  Microelectronics and nanotechnology
  Multimedia
  Telecommunications
  Other
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Brazil
  Bulgaria
  Cameroon
  Canada
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Mexico
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States


This page was published on 25/11/2005
Published: 25/11/2005

   Headlines

Last Update: 25-11-2005  
Related category(ies):
Information society  |  Health & life sciences  |  Pure sciences

 

Add to PDF "basket"

Setting the standard for electrochemotherapy

Electrochemotherapy – which combines conventional drug treatment with short high voltage pulsed electric fields to improve delivery – is an exciting new approach to treating certain types of cancer that is proving its efficacy. The EU-backed ESOPE project has developed a standard operating procedure (SOP) and equipment that will help harmonise the use of this treatment in Europe as well as reduce cost.

Regular radiotherapy machines cost around €1 million, but 'Cliniporator' could cost as little as €45 000. © Michael Anderson, National Cancer Institute
Regular radiotherapy machines cost around €1 million, but 'Cliniporator' could cost as little as €45 000.
© Michael Anderson, National Cancer Institute
Every year, 4 million new cases of cancer are diagnosed and 750 000 people die of the disease in Europe alone. As life expectancy in most European countries rises, so do cancer-related deaths. Indeed, cancer is likely to remain one of the biggest killers in the 21st century.

Although there is no known cure for cancer, there are various approaches to treating one of the industrialised world's deadliest diseases, such as radiotherapy, chemotherapy and the surgical removal of cancer tissue. A novel approach called electrochemotherapy has recently emerged to augment the medical profession's arsenal of effective weapons.

This new treatment combines conventional chemotherapeutic agents with short high voltage pulsed electric fields in order to render the membrane of the tumour cells more porous and, thus, receptive to the drugs being administered. The SOP developed by the EU-funded ESOPE project proved highly effective against cutaneous or sub-cutaneous (on or under the skin) tumours resistant to conventional cancer therapies.

ESOPE – which was funded under the previous Fifth Framework Programme's (FP5, 1998-2002) Quality of Life programme – conducted clinical studies involving 110 cancer patients, treating some 170 individual tumour nodules. Nearly three-quarters of these nodules completely disappeared, while another 11% partially regressed, making the objective response to the novel treatment an impressive 85%.

“Electrochemotherapy (or ECT) is an easy, safe and effective treatment of single or multiple nodules of any histology in the cutaneous or subcutaneous tissue,” says Dr Lluis M. Mir of France's Centre National de la Recherche Scientifique (CNRS), coordinator of the project. “It increases the quality of life of patients, with progressive disease and is an ideal treatment for tumours resistant to conventional therapies.”

Growth potential
One of the partners in the project, a European SME called Igea, developed advanced electrochemotherapy technology that is possibly the most advanced in the world. The new technology has the added bonus that its costs are low enough not only to take some of the strain off public health budgets, but to make it easier to transfer ‘Cliniporator' to developing countries.

Ruggero Cadossi of the firm Igea explained that the 'Cliniporator' would be available for €45 000 while the electrodes necessary for the treatment cost around €700 for each patient. ECT treatment is completed in one session. In contrast, radiotherapy machines are worth some €1 million, with each treatment, five to ten sessions, typically costing € 1 200 per session.

Cancer research is an ongoing commitment on the part of European national governments and the EU. Under the current FP6 (2002-2006), R&D is funded under the ‘Combating cancer' focus of the major diseases stream of the ‘Life Sciences, Genomics and Biotechnology for Health' thematic priority.

European Commission, EU project, CER 2005

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

ESOPE

EU-backed research under FP6

FP5's Quality of Life programme


Contacts
Research Contacts page
  Top   Research Information Center